ScoreWhy is Luoxin Pharmaceuticals Group Stock Co., Ltd. ?
1
Poor Management Efficiency with a low ROCE of 3.79%
- The company has been able to generate a Return on Capital Employed (avg) of 3.79% signifying low profitability per unit of total capital (equity and debt)
2
High Debt Company with a Debt to Equity ratio (avg) at times
- Poor long term growth as Net Sales has grown by an annual rate of -24.01% and Operating profit at -192.95% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
- The company has been able to generate a Return on Equity (avg) of 3.63% signifying low profitability per unit of shareholders funds
3
Poor long term growth as Net Sales has grown by an annual rate of -24.01% and Operating profit at -192.95% over the last 5 years
4
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 15.13%, its profits have risen by 4%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Luoxin Pharmaceuticals Group Stock Co., Ltd. for you?
High Risk, Medium Return
Absolute
Risk Adjusted
Volatility
Luoxin Pharmaceuticals Group Stock Co., Ltd.
22.5%
0.52
46.98%
China Shanghai Composite
14.77%
1.01
15.10%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-24.01%
EBIT Growth (5y)
-192.95%
EBIT to Interest (avg)
-2.08
Debt to EBITDA (avg)
1.04
Net Debt to Equity (avg)
0.74
Sales to Capital Employed (avg)
0.59
Tax Ratio
12.17%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
3.79%
ROE (avg)
3.63%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.89
EV to EBIT
-10.66
EV to EBITDA
-16.29
EV to Capital Employed
2.56
EV to Sales
2.75
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-23.98%
ROE (Latest)
-49.25%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend12What is working for the Company
NET PROFIT(HY)
Higher at CNY -481.34 MM
DEBTORS TURNOVER RATIO(HY)
Highest at 3.55%
RAW MATERIAL COST(Y)
Fallen by -38.66% (YoY
OPERATING PROFIT(Q)
Highest at CNY 29.28 MM
OPERATING PROFIT MARGIN(Q)
Highest at 6.13 %
PRE-TAX PROFIT(Q)
At CNY 19.38 MM has Grown at 110.44%
EPS(Q)
Highest at CNY 0.01
-14What is not working for the Company
INTEREST(HY)
At CNY 34.17 MM has Grown at 19.44%
NET SALES(Q)
At CNY 477.85 MM has Fallen at -27.23%
ROCE(HY)
Lowest at -49.51%
CASH AND EQV(HY)
Lowest at CNY 873.91 MM
DEBT-EQUITY RATIO
(HY)
Highest at 80.59 %
Here's what is working for Luoxin Pharmaceuticals Group Stock Co., Ltd.
Debtors Turnover Ratio
Highest at 3.55% and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Operating Profit
Highest at CNY 29.28 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (CNY MM)
Operating Profit Margin
Highest at 6.13 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at CNY 19.38 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (CNY MM)
Pre-Tax Profit
At CNY 19.38 MM has Grown at 110.44%
over average net sales of the previous four periods of CNY -185.65 MMMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (CNY MM)
Net Profit
Highest at CNY 5.65 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (CNY MM)
Net Profit
At CNY 5.65 MM has Grown at 103%
over average net sales of the previous four periods of CNY -188.09 MMMOJO Watch
Near term Net Profit trend is positive
Net Profit (CNY MM)
EPS
Highest at CNY 0.01
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (CNY)
Raw Material Cost
Fallen by -38.66% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Luoxin Pharmaceuticals Group Stock Co., Ltd.
Net Sales
At CNY 477.85 MM has Fallen at -27.23%
over average net sales of the previous four periods of CNY 656.62 MMMOJO Watch
Near term sales trend is extremely negative
Net Sales (CNY MM)
Interest
At CNY 34.17 MM has Grown at 19.44%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (CNY MM)
Net Sales
Lowest at CNY 477.85 MM
in the last five periodsMOJO Watch
Near term sales trend is negative
Net Sales (CNY MM)
Cash and Eqv
Lowest at CNY 873.91 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Debt-Equity Ratio
Highest at 80.59 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Non Operating Income
Highest at CNY 0.3 MM
in the last five periodsMOJO Watch
Increased income from non business activities may not be sustainable
Non Operating income
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
